Home Featured Page 195

Featured

Latest

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Q3’25 Psychedelic Lobbying Update

Psychedelics and Substance Use Disorder: 4000 BCE to Present Day

Psyched Wellness Announces Path to Market for AME-1-derived Products in the...

COMPASS Pathways announces changes in Executive Team

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial...

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with...

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and...

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office...

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...

Editor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity

Psyched Wellness Hires Del Mahabadi as Digital Marketing Consultant to Drive...

1...194195196...301 Page 195 of 301

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Q3’25 Psychedelic Lobbying Update

Psychedelics and Substance Use Disorder: 4000 BCE to Present Day

Psyched Wellness Announces Path to Market for AME-1-derived Products in the...

COMPASS Pathways announces changes in Executive Team

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial...

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with...

Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and...

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office...

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...

Editor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity

Psyched Wellness Hires Del Mahabadi as Digital Marketing Consultant to Drive...

EDITOR PICKS

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY